Dogwood Therapeutics, a clinical-stage biotech company, highlighted progress on Halneuron, a NaV1.7 inhibitor aimed at treating chemotherapy-induced neuropathic pain. The company also announced plans to start clinical trials for SP16, an LRP1 agonist designed to prevent neuropathy during chemotherapy, with funding from the National Cancer Institute. These developments focus on addressing pain and neuropathy related to cancer treatments, offering potential new options for patients suffering from these side effects.
Two Thai businessmen sued Tether in New York, challenging the company's authority to freeze about $42.4 million USDT in October 2025 without a court warrant. The freeze followed an informal request from Homeland Security Investigations amid a broader...
US federal debt has surpassed $40 trillion, driven by significant government and corporate borrowing to fund a large-scale AI data center infrastructure expansion. Despite high debt levels, the economy remains strong with a 4.1% unemployment rate in ...
iMetal Resources has appointed Michel Dufresne, a seasoned mining executive with extensive global project experience, to its board of directors. This move strengthens the company's technical leadership as it advances its Gowganda West gold project in...
The TRUMP memecoin team transferred $26 million worth of tokens to BitGo amid a price rejection near $2.50 and weak buying interest, suggesting a strategic exit rather than routine profit-taking. Despite a recent bullish momentum in the market, TRUMP...
Filecoin surged 15.41% to $0.7962, leading crypto gainers as talks of potential network upgrades sparked investor interest. Other notable gainers include Uniswap, Curve DAO, Ethena, and Sky, reflecting ongoing enthusiasm in decentralized finance and ...
